首页> 外文OA文献 >Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis
【2h】

Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis

机译:Neoadjuvant放射治疗,佐剂放疗和化疗的长期效果仅对局部晚期非小细胞肺癌的存活率进行手术:匹配分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background The optimal timing of radiotherapy (RT) with respect to surgery remains controversial for locally advanced non-small cell lung cancer (LA NSCLC) undergoing surgery and the long-term effect of neoadjuvant RT, adjuvant RT, and chemotherapy-only on survival is unknown. Methods A retrospective study with Greedy 5 → 1 Digit propensity score matching technique was performed for locally advanced NSCLC patients identified from the Surveillance, Epidemiology, and End Results (SEER) database during 2004 to 2012. Kaplan-Meier and the log-rank test were conducted to compare NSCLC-specific survival. Cox proportional hazards multivariable regression was performed to assess the impact of different treatment regimens on cancer-specific mortality after adjustment for demographic factors, histology type, tumor grade, tumor size, nodal stage, and extent of resection. Results One thousand, two hundred and seventy-eight locally advanced NSCLC patients undergoing surgery were identified after propensity matching. Cox regression analyses showed the risk of cancer-specific mortality is not significantly different among neoadjuvant RT, adjuvant RT, and chemotherapy-only. Subgroup analyses showed that for patients with T1/2 & N2/3, the surgery plus chemotherapy-only group showed markedly higher mortality risk (HR = 1.42, 95%CI:1.10–1.83) than the neoadjuvant RT group. Other risk factors include older age, higher tumor grade, larger tumor size, and greater lymph node involvement. Conclusions The findings of this study suggest that the benefit of additional neoadjuvant or adjuvant RT to chemotherapy may be linked to a proper selection of LA NSCLC patients who undergo surgery. The timing of radiotherapy should be decided on the premise of fully considering patients’ condition and the quality of life after treatment.
机译:摘要背景放疗(RT)相对于手术的最佳定时仍然是有争议的局部晚期非小细胞肺癌(LA NSCLC)接受手术和新辅助RT,佐剂RT的长期效果和化疗只对生存是未知的。方法,用于从监测,流行病学所标识本地晚期NSCLC患者中进行用贪婪5→1位数字倾向得分匹配技术的回顾性研究,和最终结果(SEER)数据库2004期间2012的Kaplan-Meier和log-rank检验是以比较非小细胞肺癌的具体生存。考克斯进行比例风险多元回归来评估不同的治疗方案对癌特异性死亡率调整人口因素,组织学类型,肿瘤分级,肿瘤大小,淋巴结阶段,和切除的程度后的冲击。结果千,接受手术的278局部晚期非小细胞肺癌患者的倾向匹配后进行鉴定。 Cox回归分析显示癌特异性死亡的风险是不新辅助RT,辅助RT之间显著不同和化疗只。亚组分析显示,患者的T1 / 2,N 2/3,手术加仅化疗组显示出显着更高的死亡风险(HR = 1.42,95%CI:1.10-1.83),比新辅助RT组。其他危险因素包括年龄,较高的肿瘤分级,肿瘤较大的尺寸和更大的淋巴结受累。结论:这项研究的结果表明,新辅助附加或辅助RT化疗的好处可以链接到谁接受手术LA NSCLC患者的正确选择。放疗的时间应在充分考虑患者病情的前提和生命的治疗后的质量来决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号